Investigating how a specific receptor affects skin inflammation in allergic contact dermatitis
Role of neurokinin 1 receptor signaling in keratinocytes in allergic contact dermatitis
This study is looking at how a specific receptor in skin cells might play a role in the inflammation and long-lasting effects of allergic contact dermatitis, with the goal of finding new treatments to help people manage their symptoms better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10898711 on NIH RePORTER |
What this research studies
This research focuses on allergic contact dermatitis (ACD), a common skin condition triggered by exposure to certain substances. The study aims to understand how the neurokinin-1 receptor (NK1R) signaling in skin cells, particularly keratinocytes, contributes to the inflammation and chronicity of ACD. By examining the cellular and molecular mechanisms involved, the researchers hope to identify potential new immunotherapies that could block NK1R and alleviate symptoms for patients suffering from this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with allergic contact dermatitis who experience chronic skin inflammation.
Not a fit: Patients with other types of dermatitis or skin conditions unrelated to allergic contact dermatitis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted treatments for patients with allergic contact dermatitis.
How similar studies have performed: Previous research has shown promise in targeting similar pathways for treating inflammatory skin conditions, suggesting potential for success in this approach.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Larregina, Adriana T — University of Pittsburgh at Pittsburgh
- Study coordinator: Larregina, Adriana T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.